Recent News

• 08.06.2026 - argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
• 08.03.2026 - argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
• 08.03.2026 - argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
• 07.27.2026 - argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
• 07.16.2026 - argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
• 06.23.2026 - argenx to Host Autoimmune Myositis R&D Webinar
• 06.03.2026 - argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
• 05.28.2026 - argenx to Host Myositis R&D Webinar on June 23, 2026
• 05.27.2026 - argenx to Present at Upcoming Investor Conferences
• 05.08.2026 - argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

Recent Filings

• 08.06.2026 - SC TO-T/A Tender offer statement by Third Party
• 08.06.2026 - SC TO-T Tender offer statement by Third Party
• 08.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.03.2026 - EX-99.1 EX-99.1
• 07.28.2026 - SC TO-C Written communication relating to an issuer or third party
• 07.27.2026 - SC TO-C Written communication relating to an issuer or third party
• 07.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.27.2026 - EX-99.1 EX-99.1
• 07.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.23.2026 - EX-99.1 EX-99.1